Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Zagociguat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tisento Therapeutics Wraps Up Global Phase 2B Zagociguat Study
    Tisento Therapeutics Wraps Up Global Phase 2B Zagociguat Study

    08 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/08/3215201/0/en/Tisento-Therapeutics-Completes-Enrollment-in-PRIZM-a-Global-Phase-2b-Study-of-Zagociguat-for-the-Treatment-of-MELAS.html

    GLOBENEWSWIRE
    08 Jan 2026
    Share Share
    First PRIZM Participant Enrolled in Tisento's MELAS Study
    First PRIZM Participant Enrolled in Tisento's MELAS Study

    20 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/20/3136285/0/en/First-PRIZM-Study-Participant-Enrolled-in-Tisento-Therapeutics-Open-Label-Extension-Study-in-MELAS.html

    GLOBENEWSWIRE
    20 Aug 2025
    Share Share
    Tisento Doses First Patient In Zagociguat Phase 2b PRIZM Study
    Tisento Doses First Patient In Zagociguat Phase 2b PRIZM Study

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015457/0/en/First-Participant-Dosed-in-Tisento-Therapeutics-Global-Phase-2b-PRIZM-Study-Evaluating-Zagociguat-for-the-Treatment-of-MELAS.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share
    Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
    Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

    11 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/11/2667449/0/en/Cyclerion-Announces-Definitive-Agreement-for-Zagociguat-and-CY3018.html

    GLOBENEWSWIRE
    11 May 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.